You are here
New Formulations of Omeprazole Delayed-Release Capsules Approved by FDA
PITTSBURGH, PA – June 2, 2003 – Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-release Capsules, 10 mg and 20 mg strengths and tentative approval for the 40 mg strength.
Omeprazole Delayed-release Capsules is the generic version of AstraZeneca LP’s Prilosec®.
More drugs or more costly drugs are being prescribed, industry trade group says
Risk approaches 13% for women who fall ill early in pregnancy
Alexion announces positive top-line results for ALXN1210 in PNH
Increased risk of high-frequency hearing loss pegged at 60%
Janssen drug targets metastatic urothelial cancer, marked by poor outcomes
Researchers say this real-world study in Canada should also apply to the U.S.
The results from a seven-year study were “entirely unexpected”
Generic competition pushed back to at least mid-2018
Report identifies critical need to minimize financial toxicity and increase access